Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Preclinical evaluation of autologous dendritic cells transfected with mRNA or loaded with apoptotic cells for immunotherapy of high-risk neuroblastoma

Cancer Gene Therapy volume 12, pages 699–707 (2005)Cite this article

Abstract

Children with high-risk neuroblastoma (NB) have a poor clinical outcome. The purpose of the present study was to evaluate different strategies for immunotherapy of high-risk NB based on vaccination with antigen-loaded dendritic cells (DCs). DCs are professional antigen-presenting cells with the ability to induce antitumor T-cell responses. We have compared DCs either loaded with apoptotic tumor cells or transfected with mRNA from the NB cell line HTB11 SK-N-SH, for their capacity to induce T-cell responses in vitro. Monocyte-derived DCs from healthy donors were loaded with tumor-derived antigens in the form of apoptotic cells or mRNA, matured and used to prime autologous T cells in vitro. After 1 week, T-cell responses against antigen-loaded DCs were measured by ELISPOT assay. DCs loaded with apoptotic NB cells or transfected with NB-cell mRNA were both able to efficiently activate autologous T cells. Both T cells of the CD8+ and CD4+ subset were activated. T cells activated by NB mRNA transfected DCs extensively crossreacted with DCs loaded with apoptotic NB cells and vice versa. The results indicate that loading of DCs with apoptotic NB cells or transfection with tumor mRNA represent promising strategies for development of individualized cancer vaccines/cancer gene therapy in treatment of NB.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9

Similar content being viewed by others

References

  1. Weinstein JL, Katzenstein HM, Cohn SL . Advances in the diagnosis and treatment of neuroblastoma. Oncologist. 2003;8:278–292.

    Article  PubMed  Google Scholar 

  2. Bowman LC, Castleberry RP, Cantor A, et al. Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study. J Natl Cancer Inst. 1997;89:373–380.

    Article  CAS  PubMed  Google Scholar 

  3. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999;341:1165–1173.

    Article  CAS  PubMed  Google Scholar 

  4. Valteau-Couanet D, Leboulaire C, Maincent K, et al. Dendritic cells for NK/LAK activation: rationale for multicellular immunotherapy in neuroblastoma patients. Blood. 2002;100:2554–2561.

    Article  CAS  PubMed  Google Scholar 

  5. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767–811.

    Article  CAS  PubMed  Google Scholar 

  6. Geiger JD, Hutchinson RJ, Hohenkirk LF, et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res. 2001;61:8513–8519.

    CAS  PubMed  Google Scholar 

  7. Kugler A, Stuhler G, Walden P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med. 2000;6:332–336.

    Article  CAS  PubMed  Google Scholar 

  8. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4:328–332.

    Article  CAS  PubMed  Google Scholar 

  9. Thurner B, Haendle I, Roder C, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med. 1999;190:1669–1678.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Saeboe-Larssen S, Fossberg E, Gaudernack G . mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT). J Immunol Methods. 2002;259:191–203.

    Article  CAS  PubMed  Google Scholar 

  11. Berard F, Blanco P, Davoust J, et al. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med. 2000;192:1535–1544.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Albert ML, Sauter B, Bhardwaj N . Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 1998;392:86–89.

    Article  CAS  PubMed  Google Scholar 

  13. Hoffmann TK, Meidenbauer N, Dworacki G, et al. Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res. 2000;60:3542–3549.

    CAS  PubMed  Google Scholar 

  14. Zhang W, He L, Yuan Z, et al. Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin. Hum Gene Ther. 1999;10:1151–1161.

    Article  CAS  PubMed  Google Scholar 

  15. Herr W, Schneider J, Lohse AW, et al. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens. J Immunol Methods. 1996;191:131–142.

    Article  CAS  PubMed  Google Scholar 

  16. Gabrilovich DI . Dendritic cell vaccines for cancer treatment. Curr Opin Mol Ther. 2002;4:452–458.

    CAS  PubMed  Google Scholar 

  17. Fukao T, Koyasu S . Expression of functional IL-2 receptors on mature splenic dendritic cells. Eur J Immunol. 2000;30:1453–1457.

    Article  CAS  PubMed  Google Scholar 

  18. Amigorena S, Lankar D, Briken V, et al. Type II and III receptors for immunoglobulin G (IgG) control the presentation of different T cell epitopes from single IgG-complexed antigens. J Exp Med. 1998;187:505–515.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Jenne L, Arrighi JF, Jonuleit H, et al. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis. Cancer Res. 2000;60:4446–4452.

    CAS  PubMed  Google Scholar 

  20. Murphy G, Ragde H, Kenny G, et al. Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients. Anticancer Res. 1995;15:1473–1479.

    CAS  PubMed  Google Scholar 

  21. Heiser A, Maurice MA, Yancey DR, et al. Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J Immunol. 2001;166:2953–2960.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Jannicke Widerberg for technical assistance with confocal microscopy and Ellen Fossberg for help with isolation of mRNA.

Author information

Authors and Affiliations

  1. Department of Pediatric Research, The National Hospital, Oslo, Norway

    Silvija Jarnjak-Jankovic, Rolf D Pettersen & Mette R K Olafsen

  2. Section for Immunotherapy, The Norwegian Radium Hospital, University of Oslo, Norway

    Silvija Jarnjak-Jankovic, Stein Sæbøe-Larssen & Gustav Gaudernack

  3. Department of Pediatrics, The National Hospital, Oslo, Norway

    Finn Wesenberg

Authors
  1. Silvija Jarnjak-Jankovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rolf D Pettersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stein Sæbøe-Larssen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Finn Wesenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mette R K Olafsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gustav Gaudernack
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gustav Gaudernack.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jarnjak-Jankovic, S., Pettersen, R., Sæbøe-Larssen, S. et al. Preclinical evaluation of autologous dendritic cells transfected with mRNA or loaded with apoptotic cells for immunotherapy of high-risk neuroblastoma. Cancer Gene Ther 12, 699–707 (2005). https://doi.org/10.1038/sj.cgt.7700820

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7700820

Keywords

This article is cited by

Search

Advanced search

Quick links